

# Financial Tear Sheet

## Corporate Profile

Fibrocell is an autologous cell and gene therapy company translating personalized biologics into medical breakthroughs. Fibrocell's most advanced product candidate, azficel-T, uses its proprietary autologous fibroblast technology and is in a Phase II clinical trial for the treatment of vocal fold scarring resulting in chronic or severe dysphonia. In collaboration with Intrexon Corporation (NYSE:XON), a leader in synthetic biology, Fibrocell is also developing gene therapies for skin and joint diseases using genetically-modified autologous fibroblasts. Fibrocell is in preclinical development of FCX-007, its orphan gene-therapy product candidate, for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). Fibrocell is also in preclinical development of FCX-013, its gene-therapy product candidate, for the treatment of linear scleroderma. In addition, Fibrocell and Intrexon will be commencing preclinical development of a gene therapy for the treatment of chronic inflammatory and degenerative diseases of the joint, including arthritis and related conditions

## Stock Information

### FCSC (Common Stock)

|                                   |                       |
|-----------------------------------|-----------------------|
| <b>Exchange</b>                   | NASDAQ CM (US Dollar) |
| <b>Financial Status Indicator</b> | D                     |
| <b>Price</b>                      | <b>\$0.76</b>         |
| <b>Change (%)</b>                 | <b>▼ 0.04 (5.00%)</b> |
| <b>Volume</b>                     | 3,930,428             |
| <b>52 Week Low</b>                | \$0.51                |
| <b>Market Cap</b>                 | \$21,550,827          |
| <b>Rolling EPS</b>                | -0.84                 |
| <b>PE Ratio</b>                   | N/A                   |
| <b>Shares Outstanding</b>         | 28,356,351            |

Data as of 05/21/18 4:00 p.m. ET



## Recent Headlines & Events

05/21/18 - 7:00 a.m.  
Fibrocell Reports on Interim Results and Progress of Phase 1/2 Clinical Trial of FCX-007 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa

| Date                  | Title  |
|-----------------------|--|
| 05/21/18 8:30 a.m. ET | <b>Fibrocell FCX-007 Conference Call &amp; Webcast</b> |

05/16/18 - 4:06 p.m.  
 Fibrocell Announces Oral Presentation at 7th  
 International Investigative Dermatology Meeting

05/10/18 - 8:00 a.m.  
 Fibrocell Reports First Quarter 2018 Financial  
 Results and Recent Highlights

### SEC Filings

| Filing Date | Form |
|-------------|------|
| 05/21/18    | 8-K  |
| 05/18/18    | 8-K  |
| 05/10/18    | 10-Q |
| 05/10/18    | 8-K  |

### Corporate Governance

|                    |                       |
|--------------------|-----------------------|
| Douglas J. Swirsky | Chairman of the Board |
| Julian P. Kirk     | Director              |
| Marc B. Mazur      | Director              |
| John Maslowski     | Director              |
| Kelvin D. Moore    | Director              |
| Marcus E. Smith    | Director              |
| Christine St.Clare | Director              |

### Ownership Summary

| Shareholders         |         |              |       |            |
|----------------------|---------|--------------|-------|------------|
|                      | Holders | Value (\$MM) | % O/S | Shares     |
| Institution          | 38      | 6.33         | 37.2  | 10,538,235 |
| Mutual Fund          | 10      | .23          | 1.4   | 394,616    |
| Director and Officer | 1       | .25          | 0.4   | 105,600    |

\*Insider values reflect direct beneficial ownership.

| Top Holders                      |             |       |              |             |
|----------------------------------|-------------|-------|--------------|-------------|
|                                  | Shares Held | % O/S | Share Change | Filing Date |
| Third Security, LLC              | 8,267,413   | 29.2  | 0            | 03/31/18    |
| MSD Partners, L.P.               | 692,960     | 2.4   | 0            | 03/31/18    |
| Point72 Asset Management, L.P.   | 400,000     | 1.4   | 200,000      | 03/31/18    |
| The Vanguard Group, Inc.         | 373,645     | 1.3   | 106,365      | 03/31/18    |
| Renaissance Technologies LLC     | 117,697     | 0.4   | -11,099      | 03/31/18    |
| Creative Planning, Inc.          | 111,090     | 0.4   | 18,000       | 03/31/18    |
| PanAgora Asset Management Inc.   | 77,947      | 0.3   | 77,947       | 03/31/18    |
| FNY Partners Fund LP             | 77,918      | 0.3   | -122,082     | 03/31/18    |
| Geode Capital Management, L.L.C. | 58,710      | 0.2   | 0            | 03/31/18    |
| Morgan Stanley Wealth Management | 54,801      | 0.2   | -1,367       | 03/31/18    |

Data provided by Nasdaq. Minimum 15 minutes delayed.